UA113966C2 - Водна рідка фармацевтична композиція, яка містить арбекацин - Google Patents

Водна рідка фармацевтична композиція, яка містить арбекацин

Info

Publication number
UA113966C2
UA113966C2 UAA201403851A UAA201403851A UA113966C2 UA 113966 C2 UA113966 C2 UA 113966C2 UA A201403851 A UAA201403851 A UA A201403851A UA A201403851 A UAA201403851 A UA A201403851A UA 113966 C2 UA113966 C2 UA 113966C2
Authority
UA
Ukraine
Prior art keywords
arbecacin
pharmaceutical composition
liquid pharmaceutical
composition containing
water liquid
Prior art date
Application number
UAA201403851A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UA113966C2 publication Critical patent/UA113966C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/226—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
    • C07H15/234—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід належить до галузі медицини і стосується водної рідкої фармацевтичної композиції для лікування або профілактики верхніх або нижніх дихальних шляхів, яка містить арбекацин і хлорид-іони; застосування арбекацину гідрохлориду для одержання вказаної композиції.
UAA201403851A 2011-09-12 2012-08-03 Водна рідка фармацевтична композиція, яка містить арбекацин UA113966C2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11180927.3A EP2567691B1 (en) 2011-09-12 2011-09-12 Aqueous compositions comprising arbekacin
PCT/EP2012/065265 WO2013037566A1 (en) 2011-09-12 2012-08-03 Aqueous compositions comprising arbekacin

Publications (1)

Publication Number Publication Date
UA113966C2 true UA113966C2 (xx) 2017-04-10

Family

ID=46642515

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201403851A UA113966C2 (xx) 2011-09-12 2012-08-03 Водна рідка фармацевтична композиція, яка містить арбекацин

Country Status (15)

Country Link
US (1) US9511143B2 (uk)
EP (2) EP2567691B1 (uk)
JP (1) JP6072801B2 (uk)
KR (1) KR101944571B1 (uk)
CN (1) CN103826611B (uk)
AU (1) AU2012307661B2 (uk)
BR (1) BR112014005538A2 (uk)
CA (1) CA2844923C (uk)
ES (2) ES2532667T3 (uk)
MX (1) MX357556B (uk)
PL (2) PL2567691T3 (uk)
PT (2) PT2567691E (uk)
RU (1) RU2604767C2 (uk)
UA (1) UA113966C2 (uk)
WO (1) WO2013037566A1 (uk)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10471083B2 (en) 2011-07-12 2019-11-12 Savara Inc. Formulations of aminoglycoside and fosfomycin in combination for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
CN105246907B (zh) 2013-05-30 2017-12-01 明治制果药业株式会社 阿贝卡星衍生物及其制造和利用
US9486462B2 (en) 2013-08-26 2016-11-08 Cardeas Pharma Corporation Formulations of aminoglycosides and fosfomycin in a combination having improved chemical properties
KR20180004168A (ko) * 2015-04-22 2018-01-10 마티나스 바이오파마 나노테크놀로지스, 인코포레이티드 마이코박테리아 감염 및 폐 질환 치료를 위한 조성물 및 방법
MX2018014752A (es) 2016-05-31 2019-04-25 Polyphor Ag Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma.
CN110483597A (zh) * 2019-09-07 2019-11-22 常州方圆制药有限公司 阿贝卡星盐酸盐的假多晶型、其制备方法及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029882A (en) * 1974-03-19 1977-06-14 Schering Corporation Selective acylation of the C-1 amino group of aminoglycoside antibiotics
JPS5651499A (en) 1979-10-01 1981-05-09 Meiji Seika Kaisha Ltd Aminoglycoside derivative and its preparation
JPS58134099A (ja) 1982-02-05 1983-08-10 Meiji Seika Kaisha Ltd アミノ配糖体抗生物質の精製法
JP3215732B2 (ja) 1992-11-27 2001-10-09 財団法人微生物化学研究会 耐性菌に有効なジベカシン誘導体またはアルベカシン誘導体とそれらの製造法
JP3215759B2 (ja) 1993-09-09 2001-10-09 財団法人微生物化学研究会 耐性菌に有効な５−置換−２″−アミノ−２″−デオキシアルベカシンとその製造法
US5958449A (en) 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
JP3213687B2 (ja) * 1995-10-09 2001-10-02 財団法人微生物化学研究会 アルベカシンと（−）−シス−１，２−エポキシプロピルホスホン酸との付加塩およびその製造法、ならびに抗菌剤
JP2001161789A (ja) 1999-12-07 2001-06-19 Sawai Pharmaceutical Co Ltd 水性注射剤
ES2222294T3 (es) 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
ATE350024T1 (de) 2003-10-15 2007-01-15 Pari Gmbh Flüssige zubereitung enthaltend tobramycin
PT2316419E (pt) 2004-05-17 2012-10-22 Gilead Sciences Inc Combinação de fosfomicina/aminoglicósido em aerossol para o tratamento de infeções respiratórias bacterianas
DE102005038619A1 (de) 2005-08-16 2007-02-22 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit einer Ampulle für die Bevorratung eines zu vernebelnden Medikaments
WO2008043825A2 (en) * 2006-10-11 2008-04-17 Laboratoires Smb S.A. Pharmaceutical anti-infective composition for inhalation.
EP2030644A1 (en) 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
DE102007056462B4 (de) 2007-11-23 2011-10-27 Pari Pharma Gmbh Einwegampulle für eine Vorrichtung zur Erzeugung von Aerosolen
DE102008022987A1 (de) 2008-05-09 2009-11-12 Pari Pharma Gmbh Vernebler für Beatmungsmaschinen und Beatmungsmaschine mit einem solchen Vernebler
CN101575354B (zh) * 2009-05-26 2013-03-13 北京化工大学 阿贝卡星及其中间体地贝卡星的合成方法
CA2784207C (en) * 2009-12-14 2018-06-05 Chiesi Farmaceutici S.P.A. Antibiotic microparticles for inhalation
JP5651499B2 (ja) 2011-03-01 2015-01-14 カヤバ工業株式会社 フロントフォーク用の姿勢維持具

Also Published As

Publication number Publication date
EP2755635B1 (en) 2015-10-14
AU2012307661A1 (en) 2014-02-20
PL2567691T3 (pl) 2015-05-29
PL2755635T3 (pl) 2016-03-31
CA2844923A1 (en) 2013-03-21
JP2014526481A (ja) 2014-10-06
US20140343005A1 (en) 2014-11-20
EP2567691A1 (en) 2013-03-13
WO2013037566A1 (en) 2013-03-21
CA2844923C (en) 2019-04-30
PT2567691E (pt) 2015-04-09
ES2532667T3 (es) 2015-03-30
JP6072801B2 (ja) 2017-02-01
EP2567691B1 (en) 2014-12-24
CN103826611B (zh) 2016-10-19
EP2755635A1 (en) 2014-07-23
MX2014002465A (es) 2014-08-01
AU2012307661B2 (en) 2017-02-02
RU2604767C2 (ru) 2016-12-10
CN103826611A (zh) 2014-05-28
US9511143B2 (en) 2016-12-06
ES2555462T3 (es) 2016-01-04
PT2755635E (pt) 2016-02-10
KR101944571B1 (ko) 2019-01-31
BR112014005538A2 (pt) 2017-03-21
KR20140090598A (ko) 2014-07-17
MX357556B (es) 2018-07-13
RU2014114512A (ru) 2015-10-27

Similar Documents

Publication Publication Date Title
PH12017501306A1 (en) Inhibitors of histone demethylases
EA201991484A1 (ru) Лекарственные формы энзалутамида
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
SMT201600055B (it) Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
IN2015DN01156A (uk)
BR112015003376A8 (pt) composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
PH12016500433A1 (en) Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
EA201591166A1 (ru) Ингибиторы аутотаксина
IN2014DN10670A (uk)
UA113966C2 (xx) Водна рідка фармацевтична композиція, яка містить арбекацин
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
EA201591698A1 (ru) Макроциклические ингибиторы киназы lrrk2
EA201590460A1 (ru) Способ и средство для лечения и профилактики заболеваний, вызываемых (+)рнк-содержащими вирусами
EA201171414A1 (ru) Ингибиторы белков семейства iap
FR2997837B1 (fr) Dispositif d'osteosynthese pour le traitement des fractures du col de femur.
EA201500669A1 (ru) Офтальмологическая фармацевтическая композиция для наружного применения, содержащая регорафениб
UA115307C2 (uk) Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
EA201591184A1 (ru) Применение пидотимода для лечения атопического дерматита
PH12015501179A1 (en) Fixed dose pharmaceutical composition comprising mometasone and azelastine
EA201492161A1 (ru) N-метил-4-бензилкарбамидопиридиний хлорид и способ его получения